NASDAQ
Cytek Biosciences, Inc. (CTKB)
♥ 578 Thanks from members
Cytek Biosciences (CTKB) reported Q2 2026 revenue growth of 6% to $48.1M, driven by strong U.S. and China performance, leading to raised full-year guidance of $207–$212M, despite a widening net loss of $12.2M and ongoing European headwinds.